Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development.

ABSTRACT: The US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) guidances on small-molecule drug-drug interactions (DDIs), with input from the International Transporter Consortium (ITC), recommend the evaluation of nine drug transporters. Although other clinically relevant drug uptake and efflux transporters have been discussed in ITC white papers, they have been excluded from further recommendation by the ITC and are not included in current regulatory guidances. These include the ubiquitously expressed equilibrative nucleoside transporters (ENT) 1 and ENT2, which have been recognized by the ITC for their potential role in clinically relevant nucleoside analog drug interactions for patients with cancer. Although there is com

SUBMITTER: Hau RK 

PROVIDER: S-EPMC11347013 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature